ReviewOxidative medicine and cellular longevity2019
Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases.
Review in Oxidative medicine and cellular longevity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed, 5 syntheses or guidelines pooled it, 321 citations in OpenAlex.
- Salivary metabolites for pancreatic cancer diagnosis: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Cardiovascular complications in a diabetes prediction model using machine learning: a systematic review.Cardiovascular diabetology · 2023Pooled it
- Effect of breathing exercises on oxidative stress biomarkers in humans: A systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- GLP-1a: Going beyond Traditional Use.International journal of molecular sciences · 2022Pooled it
- Effects ofFrontiers in nutrition · 2020Pooled it
- Trial
- Circuit training on oxidative stress and arterial health: a health promotion perspective for obese adult men.Frontiers in public health · 2025Trial
- Antioxidant Efficacy of aMarine drugs · 2022Trial
- Dose-dependent effects of anthocyanin supplementation on platelet function in subjects with dyslipidemia: A randomized clinical trial.EBioMedicine · 2021Trial
- Anthocyanin supplementation improves anti-oxidative and anti-inflammatory capacity in a dose-response manner in subjects with dyslipidemia.Redox biology · 2020Trial
- Artificial Intelligence-Powered Histopathology in Stem Cell Research: Bridging Morphology, Function, and Omics.Current issues in molecular biology · 2026Review
- Metabolic Syndrome and Pancreatic Cancer: Linking Insulin Resistance, Inflammation, and Carcinogenesis.Diagnostics (Basel, Switzerland) · 2026Review
- Metabolic Syndrome and Male Infertility: The Role of Obesity and Chronic Inflammation.Biomedicines · 2026Review
- Oxidative Stress Biomarkers and Their Association with Interleukin-6 in Patients with Obstructive Sleep Apnea: A Cross-Sectional Study.International journal of molecular sciences · 2026Observational
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Role of Plant-Derived Antioxidants in Oxidative Stress-Associated Myocardial Infarction: Structure-Activity Relationship (SAR)-Based Mechanistic Insights.Molecules (Basel, Switzerland) · 2026Review
- Metabolomic Profile, Antioxidant Capacity, and Preliminary Cellular Activity ofMolecules (Basel, Switzerland) · 2026Article
- Very-Low-Energy Ketogenic Therapy Modulates the Metabolic-Antioxidant Axis in Patients with Obesity and Type 2 Diabetes: A Non-Randomized Clinical Trial.Antioxidants (Basel, Switzerland) · 2026Article
- Oxidative Stress in Dry Eye Disease: Molecular Mechanisms and Emerging Therapeutic Strategies.Biomolecules · 2026Review
- High-intensity interval training andResearch in pharmaceutical sciences · 2026Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MS) represents worldwide public health issue characterized by a set of cardiovascular risk factors including obesity, diabetes, dyslipidemia, hypertension, and impaired glucose tolerance. The link between the MS and the associated diseases is represented by oxidative stress (OS) and by the intracellular redox imbalance, both caused by the persistence of chronic inflammatory conditions that characterize MS. The increase in oxidizing species formation in MS has been accepted as a major underlying mechanism for mitochondrial dysfunction, accumulation of protein and lipid oxidation products, and impairment of the antioxidant systems. These oxidative modifications are recognized as relevant OS biomarkers potentially able to (i) clarify the role of reactive oxygen and nitrogen species in the etiology of the MS, (ii) contribute to the diagnosis/evaluation of the disease's severity, and (iii) evaluate the utility of possible therapeutic strategies based on natural antioxidants. The antioxidant therapies indeed could be able to (i) counteract systemic as well as mitochondrial-derived OS, (ii) enhance the endogenous antioxidant defenses, (iii) alleviate MS symptoms, and (iv) prevent the complications linked to MS-derived cardiovascular diseases. The focus of this review is to summarize the current knowledge about the role of OS in the development of metabolic alterations characterizing MS, with particular regard to the occurrence of OS-correlated biomarkers, as well as to the use of therapeutic strategies based on natural antioxidants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.